AMLX NASDAQ
Amylyx Pharmaceuticals, Inc.
1W: -1.6%
1M: -5.2%
3M: +43.4%
YTD: +147.8%
1Y: +99.7%
3Y: +68.0%
$28.30
+1.21 (+4.47%)
Weekly Expected Move ±6.1%
$24
$26
$27
$29
$31
Credit Risk of going bust: lower than 78% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Amylyx Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $3.55B.
Distance to default 9.17 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 76.0%; Altman Z'' 1.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Amylyx Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $3.55B.
Distance to default 9.17 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 76.0%; Altman Z'' 1.60. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2024-06-21
Earliest Filing
2024-07-10
Latest Filing
target: 2
acquirer: 1
Counterparties (Filed by AMLX)
3 relationshipsCompanies named in AMLX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Eiger BioPharmaceuticals, Inc. | — | target | Sold Avexitide asset rights to Amylyx Pharmaceuticals, Inc. | 2024-07-10 | View |
| Amylyx Pharmaceuticals, Inc. | AMLX | acquirer | Acquired substantially all assets related to Avexitide from Eiger BioPharmaceuticals, Inc. | 2024-06-21 | View |
| Eiger BioPharmaceuticals, Inc. | — | target | Sold substantially all assets related to Avexitide to Amylyx Pharmaceuticals, Inc. | 2024-06-21 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Material Agreement | Agreement | View |
| 2026-08-20 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-18 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-18 | Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-24 | Regulation FD; Exhibits | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-10 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-27 | Other Events | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-10 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-12-30 | Regulation FD Disclosure | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR